Exelixis logged a -8.7% change during today's afternoon session, and is now trading at a price of $19.28 per share. On average, analysts give it a target price of $25.76.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The mid-cap company is based in the United States.
What to Consider if You Are Thinking of Buying Exelixis:
Exelixis has moved 18.0% over the last year.
EXEL has a forward P/E ratio of 20.7 based on its EPS guidance of 0.93.
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 2.3%.
The company has a price to earnings growth (PEG) ratio of 0.66.
Its Price to Book (P/B) ratio is 2.44
Exelixis Has Irregular Cash Flows
|Date Reported||Cash Flow from Operations ($ k)||Capital expenditures ($ k)||Free Cash Flow ($ k)||YoY Growth (%)|
Exelixis's free cash flows have a decent average of $376.63 Million over the last 6 years, but they are highly variable since their coefficient of variability is 452305452.2%. The compounded average growth rate over this period is 0.0%.